• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses.

作者信息

Abu-Raddad Laith J, Chemaitelly Hiam, Yassine Hadi M, Benslimane Fatiha M, Al Khatib Hebah A, Tang Patrick, Malek Joel A, Coyle Peter, Ayoub Houssein H, Al Kanaani Zaina, Al Kuwari Einas, Jeremijenko Andrew, Kaleeckal Anvar Hassan, Latif Ali Nizar, Shaik Riyazuddin Mohammad, Abdul Rahim Hanan F, Nasrallah Gheyath K, Al Kuwari Mohamed Ghaith, Al Romaihi Hamad Eid, Al-Thani Mohamed H, Al Khal Abdullatif, Butt Adeel A, Bertollini Roberto

机构信息

Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar.

World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation - Education City, Doha, Qatar.

出版信息

J Travel Med. 2021 Oct 11;28(7). doi: 10.1093/jtm/taab083.

DOI:10.1093/jtm/taab083
PMID:34050372
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8194836/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f3f/8506467/aa487badad44/taab083f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f3f/8506467/aa487badad44/taab083f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f3f/8506467/aa487badad44/taab083f1.jpg

相似文献

1
Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses.辉瑞-生物科技mRNA疫苗BNT162b2一剂与两剂接种后对新冠病毒变异株的防护效果
J Travel Med. 2021 Oct 11;28(7). doi: 10.1093/jtm/taab083.
2
The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 ≥7 days after the 2nd dose.BNT162b2（辉瑞/生物科技）疫苗在第 2 剂接种后 ≥7 天对 COVID-19 的有效率为 95%。
Ann Intern Med. 2021 Feb;174(2):JC15. doi: 10.7326/ACPJ202102160-015. Epub 2021 Feb 2.
3
COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.COVID-19 疫苗：辉瑞/生物科技和 Moderna 疫苗的生物学、药理学特征和不良反应比较。
Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1663-1669. doi: 10.26355/eurrev_202102_24877.
4
Comparison of BNT162b2 (Pfizer-BioNtech) and mRNA-1273 (Moderna) SARS-CoV-2 mRNA vaccine immunogenicity in dialysis patients.BNT162b2（辉瑞-生物科技公司）和mRNA-1273（莫德纳公司）SARS-CoV-2 mRNA疫苗在透析患者中的免疫原性比较。
Kidney Int. 2021 Sep;100(3):697-698. doi: 10.1016/j.kint.2021.07.004. Epub 2021 Jul 13.
5
A 59-Year-Old Woman with Extensive Deep Vein Thrombosis and Pulmonary Thromboembolism 7 Days Following a First Dose of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine.一位 59 岁女性，在接种第一剂辉瑞-生物科技 BNT162b2 mRNA COVID-19 疫苗后 7 天出现广泛的深静脉血栓形成和肺血栓栓塞症。
Am J Case Rep. 2021 Jun 12;22:e932946. doi: 10.12659/AJCR.932946.
6
Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.立陶宛血液系统恶性肿瘤患者的 BNT162b2 COVID-19 mRNA 疫苗免疫原性和早期临床结局：一项全国前瞻性队列研究。
Lancet Haematol. 2021 Aug;8(8):e583-e592. doi: 10.1016/S2352-3026(21)00169-1. Epub 2021 Jul 2.
7
Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech).肾移植受者对 BNT162b2（辉瑞-生物科技）接种 SARS-CoV-2 疫苗的体液免疫反应受损。
Viruses. 2021 Apr 25;13(5):756. doi: 10.3390/v13050756.
8
Perimyocarditis in Adolescents After Pfizer-BioNTech COVID-19 Vaccine.青少年接种辉瑞-生物科技新冠疫苗后的心肌炎。
J Pediatric Infect Dis Soc. 2021 Nov 11;10(10):962-966. doi: 10.1093/jpids/piab060.
9
Viral-like Reaction or Hypersensitivity? Erythema Multiforme Minor Reaction and Moderate Eosinophilia After the Pfizer-BioNTech BNT162b2 (mRNA-Based) SARS-CoV-2 Vaccine.病毒样反应还是超敏反应？辉瑞-生物科技公司BNT162b2（基于信使核糖核酸的）严重急性呼吸综合征冠状病毒2疫苗接种后的轻症多形红斑反应和中度嗜酸性粒细胞增多症
J Investig Allergol Clin Immunol. 2021 Feb 21;32(1):77-78. doi: 10.18176/jiaci.0757. Epub 2021 Sep 30.
10
[Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers].BNT162b2 mRNA新冠疫苗在医护人员中的免疫原性和安全性
Orv Hetil. 2021 Sep 26;162(39):1551-1557. doi: 10.1556/650.2021.32363.

引用本文的文献

1
Effectiveness of ChAdOx1 nCoV-19 (Vaxzevria) primary series vaccine against SARS-CoV-2 beta and delta variants: a nationwide study.ChAdOx1 nCoV-19（Vaxzevria）初级系列疫苗对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）贝塔和德尔塔变异株的有效性：一项全国性研究。
BMC Infect Dis. 2025 Aug 17;25(1):1028. doi: 10.1186/s12879-025-11410-7.
2
Current landscape of innovative drug development and regulatory support in China.中国创新药物研发与监管支持的现状
Signal Transduct Target Ther. 2025 Jul 22;10(1):220. doi: 10.1038/s41392-025-02267-y.
3
Immune histories and natural infection protection during the omicron era.

本文引用的文献

1
Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants.BNT162b2新冠疫苗对B.1.1.7和B.1.351变异株的有效性
N Engl J Med. 2021 Jul 8;385(2):187-189. doi: 10.1056/NEJMc2104974. Epub 2021 May 5.
2
The test-negative design for estimating influenza vaccine effectiveness.应用病例对照研究估计流感疫苗效力。
Vaccine. 2013 Apr 19;31(17):2165-8. doi: 10.1016/j.vaccine.2013.02.053. Epub 2013 Mar 13.
奥密克戎时代的免疫史与自然感染防护
Commun Med (Lond). 2025 Jul 1;5(1):262. doi: 10.1038/s43856-025-00974-9.
4
Assessing healthy vaccinee effect in COVID-19 vaccine effectiveness studies: a national cohort study in Qatar.评估新冠病毒疫苗有效性研究中的健康接种者效应：卡塔尔的一项全国队列研究。
Elife. 2025 Jun 9;14:e103690. doi: 10.7554/eLife.103690.
5
Protection conferred by SARS-CoV-2 infection across a spectrum of reinfection symptoms and severities.新型冠状病毒2感染对一系列再次感染症状和严重程度所提供的保护。
BMJ Open Respir Res. 2025 Mar 26;12(1):e002718. doi: 10.1136/bmjresp-2024-002718.
6
BNT162b2 Versus mRNA-1273 Vaccines: Comparative Analysis of Long-Term Protection Against SARS-CoV-2 Infection and Severe COVID-19 in Qatar.BNT162b2 与 mRNA-1273 疫苗：卡塔尔长期预防 SARS-CoV-2 感染和重症 COVID-19 的比较分析。
Influenza Other Respir Viruses. 2024 Oct;18(10):e13357. doi: 10.1111/irv.13357.
7
Assessing the impacts of vaccination and viral evolution in contact networks.评估疫苗接种和病毒进化在接触网络中的影响。
Sci Rep. 2024 Jul 8;14(1):15753. doi: 10.1038/s41598-024-66070-5.
8
Association between obstructive sleep apnea (OSA) and COVID-19 severity.阻塞性睡眠呼吸暂停（OSA）与新型冠状病毒肺炎（COVID-19）严重程度之间的关联。
J Sleep Res. 2025 Apr;34(2):e14260. doi: 10.1111/jsr.14260. Epub 2024 Jun 12.
9
Estimating protection afforded by prior infection in preventing reinfection: applying the test-negative study design.估算既往感染在预防再次感染方面提供的保护：应用病例对照研究设计。
Am J Epidemiol. 2024 Jun 3;193(6):883-897. doi: 10.1093/aje/kwad239.
10
Pfizer-BioNTech mRNA Vaccine Protection among Children and Adolescents Aged 12-17 Years against COVID-19 Infection in Qatar.辉瑞-生物科技mRNA疫苗对卡塔尔12至17岁儿童和青少年预防新冠病毒感染的效果
Vaccines (Basel). 2023 Sep 25;11(10):1522. doi: 10.3390/vaccines11101522.